Sanofi (NYSE:SNY) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

A number of other equities analysts also recently commented on SNY. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Monday. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “sell” rating in a research report on Tuesday. Guggenheim began coverage on Sanofi in a research report on Monday, October 8th. They set a “neutral” rating on the stock. BNP Paribas upgraded Sanofi from a “neutral” rating to an “outperform” rating in a research report on Wednesday, August 1st. Finally, TheStreet upgraded Sanofi from a “c+” rating to a “b” rating in a research report on Thursday, July 12th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $49.00.

Sanofi stock traded up $0.33 during trading on Wednesday, reaching $44.68. 975,700 shares of the company were exchanged, compared to its average volume of 1,882,403. Sanofi has a 52-week low of $37.43 and a 52-week high of $50.04. The company has a market cap of $112.04 billion, a price-to-earnings ratio of 14.27, a PEG ratio of 2.40 and a beta of 0.82. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 EPS for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.02. Sanofi had a return on equity of 23.77% and a net margin of 10.29%. The firm had revenue of $8.18 billion for the quarter, compared to the consensus estimate of $8.27 billion. During the same quarter last year, the business posted $1.35 earnings per share. The firm’s revenue was down 5.6% compared to the same quarter last year. On average, analysts predict that Sanofi will post 3.14 EPS for the current fiscal year.

In other Sanofi news, major shareholder Sanofi sold 104,552 shares of Sanofi stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.00% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Institute for Wealth Management LLC. raised its position in Sanofi by 27.4% in the second quarter. Institute for Wealth Management LLC. now owns 31,936 shares of the company’s stock valued at $1,278,000 after purchasing an additional 6,860 shares during the period. Van ECK Associates Corp raised its position in Sanofi by 15.1% in the second quarter. Van ECK Associates Corp now owns 361,195 shares of the company’s stock valued at $14,451,000 after purchasing an additional 47,420 shares during the period. Signaturefd LLC raised its position in Sanofi by 32.0% in the second quarter. Signaturefd LLC now owns 10,266 shares of the company’s stock valued at $411,000 after purchasing an additional 2,486 shares during the period. Providence Capital Advisors LLC raised its position in Sanofi by 46.0% in the second quarter. Providence Capital Advisors LLC now owns 30,016 shares of the company’s stock valued at $1,201,000 after purchasing an additional 9,460 shares during the period. Finally, Nomura Holdings Inc. raised its position in Sanofi by 51.8% in the second quarter. Nomura Holdings Inc. now owns 50,726 shares of the company’s stock valued at $2,030,000 after purchasing an additional 17,310 shares during the period. Institutional investors own 7.54% of the company’s stock.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: What is a stock split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.